STOCK TITAN

Iridex SEC Filings

IRIX Nasdaq

Welcome to our dedicated page for Iridex SEC filings (Ticker: IRIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Want to know how sales of MicroPulse® laser consoles are trending or whether insiders are buying stock before new clinical data? This Iridex SEC filings hub starts where most ophthalmology investors begin—searching for hard-to-find data hidden in 10-Ks and 10-Qs. From cash flow tied to disposable probe sales to FDA-related 8-K disclosures, every document is organized and tagged so you can stop hunting and start analyzing.

Use Stock Titan’s AI to move straight to answers. Our algorithms deliver Iridex SEC filings explained simply: instant highlights of revenue by product line, flags on R&D spending changes, and side-by-side Iridex earnings report filing analysis. Need quick transaction intel? Receive Iridex Form 4 insider transactions real-time alerts that clarify Iridex executive stock transactions Form 4 in plain language. Each link opens the original EDGAR text plus an AI summary that answers common queries like “How did gross margin shift this quarter?” or “Which directors exercised options?”

  • 10-K: The Iridex annual report 10-K simplified pinpoints consumable vs. console revenue and global distributor performance.
  • 10-Q: Read the latest Iridex quarterly earnings report 10-Q filing with AI-generated trend notes.
  • Form 4: Track Iridex insider trading Form 4 transactions moments after they post.
  • 8-K: Critical announcements—Iridex 8-K material events explained without jargon.
  • DEF 14A: The Iridex proxy statement executive compensation section highlights incentive alignment with glaucoma therapy milestones.

Whether you’re understanding Iridex SEC documents with AI for the first time or comparing quarter-over-quarter adoption of retina lasers, our real-time feed and concise commentary turn dense filings into actionable insights.

Rhea-AI Summary

Patrick Mercer, President and CEO of IRIDEX CORP (IRIX), reported a sale of 23,850 shares on 10/01/2025 at a reported price of $1.13 per share. After the transaction Mercer beneficially owns 392,007 shares, reported as direct ownership. The Form 4 was signed by an attorney-in-fact on 10/02/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Romeo R. Dizon, Chief Financial Officer of IRIDEX Corp (IRIX), reported purchases of common stock on 09/12/2025. The Form 4 shows two non-derivative acquisitions: 250 shares at $1.37 and 1,200 shares at $1.36, for a total of 1,450 shares acquired. Following the transactions, the filing reports 61,950 shares beneficially owned. The form is signed by an attorney-in-fact on 09/15/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Romeo R. Dizon, the Chief Financial Officer and a director of Iridex Corp (IRIX), reported insider purchases on 09/10/2025. He acquired 1,000 shares at $1.33 and 500 shares at $1.36, bringing his total reported beneficial ownership to 59,250 shares. The Form 4 was signed by an attorney-in-fact on 09/11/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Iridex Corp (IRIX) insider purchase: Chief Financial Officer Romeo R. Dizon purchased 1,500 shares of Iridex common stock on 09/09/2025 at a price of $1.37 per share. Following the transaction, the reporting person beneficially owns 57,750 shares. The Form 4 was filed indicating the transaction code "P" and was signed by an attorney-in-fact on 09/10/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Filing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
current report
-
Rhea-AI Summary

Romeo R. Dizon, Chief Financial Officer of IRIDEX Corp (IRIX), reported an insider purchase of common stock. On 09/08/2025 he acquired 500 shares at $1.40 per share, increasing his reported beneficial ownership to 56,250 shares. The Form 4 was signed on 09/09/2025 by an attorney-in-fact.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
insider
Rhea-AI Summary

Iridex Corp (IRIX) insider purchase reported: Chief Financial Officer Romeo R. Dizon acquired 1,000 shares of Iridex common stock on 09/05/2025 at $1.35 per share, increasing his beneficial ownership to 55,750 shares. The Form 4 was signed by an attorney-in-fact on 09/08/2025. No derivative transactions or additional details were reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Iridex Corp (IRIX) Form 4: Romeo R. Dizon, identified as the Chief Financial Officer, reported three transactions on 09/04/2025. The filing shows acquisitions of 404, 96, and 625 common shares at prices of $1.32, $1.345, and $1.39 respectively. After those transactions the filing lists beneficial ownership totals of 54,029, 54,125, and 54,750 shares. The form was signed by an attorney-in-fact on 09/05/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Iridex Corp (IRIX) insider filing shows Chief Financial Officer Romeo R. Dizon, via attorney-in-fact, purchased 625 shares of common stock on 09/03/2025 at $1.36 per share, bringing his beneficial ownership to 53,625 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Romeo R. Dizon, Chief Financial Officer of Iridex Corp (IRIX), reported a purchase of 625 shares of the company's common stock on 09/02/2025 at a price of $1.34 per share, increasing his beneficial ownership to 53,000 shares. The Form 4 was signed by an attorney-in-fact on 09/03/2025. The filing documents a routine insider purchase by a named officer and identifies no derivative transactions or additional disclosures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

What is the current stock price of Iridex (IRIX)?

The current stock price of Iridex (IRIX) is $1.09 as of October 8, 2025.

What is the market cap of Iridex (IRIX)?

The market cap of Iridex (IRIX) is approximately 18.9M.
Iridex

Nasdaq:IRIX

IRIX Rankings

IRIX Stock Data

18.86M
12.25M
27.64%
15.83%
1.6%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
MOUNTAIN VIEW